Phase II study of treatment for newly diagnosed multiple myeloma patients over 75 years old with alternating bortezomib/dexamethasone and lenalidomide/dexamethasone: The MARBLE trial

Akihiro Yokoyama, Akiko Kada, Akiko M. Saito, Morio Sawamura, Takuya Komeno, Kazutaka Sunami, Naoki Takezako

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Elderly multiple myeloma (MM) patients, who are generally ineligible for transplantation, have high risks of death and treatment discontinuation, and require a regimen incorporating novel agents that balance safety, tolerability, and efficacy. We evaluated alternating bortezomib-dexamethasone and lenalidomide-dexamethasone treatments administered over a 63-day cycle in transplant-ineligible elderly patients with newly diagnosed MM. Subcutaneous bortezomib 1.3 mg/m2 was administered weekly on Days 1, 8, 15, and 22; oral lenalidomide 15 mg daily on Days 36-56; and oral dexamethasone 20 mg on Days 1, 8, 15, 22, 36, 43, 50, and 57 for 6 cycles. The primary endpoint was the overall response rate.

Original languageEnglish
Pages (from-to)547-552
Number of pages6
JournalActa Medica Okayama
Volume73
Issue number6
Publication statusPublished - 2019
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • General Biochemistry,Genetics and Molecular Biology

Fingerprint

Dive into the research topics of 'Phase II study of treatment for newly diagnosed multiple myeloma patients over 75 years old with alternating bortezomib/dexamethasone and lenalidomide/dexamethasone: The MARBLE trial'. Together they form a unique fingerprint.

Cite this